{"id":2972,"date":"2023-07-19T15:37:38","date_gmt":"2023-07-19T13:37:38","guid":{"rendered":"https:\/\/p664637.webspaceconfig.de\/izb-biotech-news\/neutralizing-gdf-15-development-of-a-new-class-of-immunotherapies-to-fight-cancer\/"},"modified":"2026-07-16T16:06:27","modified_gmt":"2026-07-16T14:06:27","slug":"neutralizing-gdf-15-development-of-a-new-class-of-anti-cancer-immunotherapy","status":"publish","type":"izb-biotech-news","link":"https:\/\/p664637.webspaceconfig.de\/en\/izb-biotech-news\/neutralizing-gdf-15-development-of-a-new-class-of-anti-cancer-immunotherapy\/","title":{"rendered":"Neutralizing GDF-15: Development of a new class of anti-cancer immunotherapy"},"content":{"rendered":"","protected":false},"excerpt":{"rendered":"<p>CatalYm combines \"good, old, effective\" antibody technology with novel biology<\/p>\n","protected":false},"featured_media":973,"parent":0,"menu_order":0,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[80,81],"tags":[],"class_list":["post-2972","izb-biotech-news","type-izb-biotech-news","status-publish","format-standard","has-post-thumbnail","hentry","category-izb-news-en","category-izb-biotech-news-en"],"acf":[],"acf_migration":{"izb_related_company":"355"},"wpml_migration":{"language_code":"en","source_language_code":"de","trid":"10918"},"yoast_migration":{"_yoast_wpseo_metadesc":"CatalYm combines \"good, old, effective\" antibody technology with novel biology"},"permalink_migration":{"custom_uri":"izb-biotech-news\/neutralizing-gdf-15-development-of-a-new-class-of-anti-cancer-immunotherapy"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Neutralizing GDF-15: Development of a new class of anti-cancer immunotherapy - IZB Innovations- und Gr\u00fcnderzentrum Biotechnologie.<\/title>\n<meta name=\"description\" content=\"CatalYm combines &quot;good, old, effective&quot; antibody technology with novel biology\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/p664637.webspaceconfig.de\/en\/izb-biotech-news\/neutralizing-gdf-15-development-of-a-new-class-of-anti-cancer-immunotherapy\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Neutralizing GDF-15: Development of a new class of anti-cancer immunotherapy - IZB Innovations- und Gr\u00fcnderzentrum Biotechnologie.\" \/>\n<meta property=\"og:description\" content=\"CatalYm combines &quot;good, old, effective&quot; antibody technology with novel biology\" \/>\n<meta property=\"og:url\" content=\"https:\/\/p664637.webspaceconfig.de\/en\/izb-biotech-news\/neutralizing-gdf-15-development-of-a-new-class-of-anti-cancer-immunotherapy\/\" \/>\n<meta property=\"og:site_name\" content=\"IZB Innovations- und Gr\u00fcnderzentrum Biotechnologie.\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-16T14:06:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/p664637.webspaceconfig.de\/wp-content\/uploads\/2024\/09\/CatalYm_Video-Thumb_600x383-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"600\" \/>\n\t<meta property=\"og:image:height\" content=\"383\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/p664637.webspaceconfig.de\\\/en\\\/izb-biotech-news\\\/neutralizing-gdf-15-development-of-a-new-class-of-anti-cancer-immunotherapy\\\/\",\"url\":\"https:\\\/\\\/p664637.webspaceconfig.de\\\/en\\\/izb-biotech-news\\\/neutralizing-gdf-15-development-of-a-new-class-of-anti-cancer-immunotherapy\\\/\",\"name\":\"Neutralizing GDF-15: Development of a new class of anti-cancer immunotherapy - IZB Innovations- und Gr\u00fcnderzentrum Biotechnologie.\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/p664637.webspaceconfig.de\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/p664637.webspaceconfig.de\\\/en\\\/izb-biotech-news\\\/neutralizing-gdf-15-development-of-a-new-class-of-anti-cancer-immunotherapy\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/p664637.webspaceconfig.de\\\/en\\\/izb-biotech-news\\\/neutralizing-gdf-15-development-of-a-new-class-of-anti-cancer-immunotherapy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/p664637.webspaceconfig.de\\\/wp-content\\\/uploads\\\/2024\\\/09\\\/CatalYm_Video-Thumb_600x383-1.jpg\",\"datePublished\":\"2023-07-19T13:37:38+00:00\",\"dateModified\":\"2026-07-16T14:06:27+00:00\",\"description\":\"CatalYm combines \\\"good, old, effective\\\" antibody technology with novel biology\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/p664637.webspaceconfig.de\\\/en\\\/izb-biotech-news\\\/neutralizing-gdf-15-development-of-a-new-class-of-anti-cancer-immunotherapy\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/p664637.webspaceconfig.de\\\/en\\\/izb-biotech-news\\\/neutralizing-gdf-15-development-of-a-new-class-of-anti-cancer-immunotherapy\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/p664637.webspaceconfig.de\\\/en\\\/izb-biotech-news\\\/neutralizing-gdf-15-development-of-a-new-class-of-anti-cancer-immunotherapy\\\/#primaryimage\",\"url\":\"https:\\\/\\\/p664637.webspaceconfig.de\\\/wp-content\\\/uploads\\\/2024\\\/09\\\/CatalYm_Video-Thumb_600x383-1.jpg\",\"contentUrl\":\"https:\\\/\\\/p664637.webspaceconfig.de\\\/wp-content\\\/uploads\\\/2024\\\/09\\\/CatalYm_Video-Thumb_600x383-1.jpg\",\"width\":600,\"height\":383},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/p664637.webspaceconfig.de\\\/en\\\/izb-biotech-news\\\/neutralizing-gdf-15-development-of-a-new-class-of-anti-cancer-immunotherapy\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/p664637.webspaceconfig.de\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"IZB Biotech News\",\"item\":\"https:\\\/\\\/p664637.webspaceconfig.de\\\/izb-biotech-news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Neutralizing GDF-15: Development of a new class of anti-cancer immunotherapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/p664637.webspaceconfig.de\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/p664637.webspaceconfig.de\\\/en\\\/\",\"name\":\"IZB Innovations- und Gr\u00fcnderzentrum Biotechnologie.\",\"description\":\"Der Ort f\u00fcr Biotech-Start-ups in M\u00fcnchen: Labore, B\u00fcror\u00e4ume, Netzwerk!\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/p664637.webspaceconfig.de\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Neutralizing GDF-15: Development of a new class of anti-cancer immunotherapy - IZB Innovations- und Gr\u00fcnderzentrum Biotechnologie.","description":"CatalYm combines \"good, old, effective\" antibody technology with novel biology","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/p664637.webspaceconfig.de\/en\/izb-biotech-news\/neutralizing-gdf-15-development-of-a-new-class-of-anti-cancer-immunotherapy\/","og_locale":"en_US","og_type":"article","og_title":"Neutralizing GDF-15: Development of a new class of anti-cancer immunotherapy - IZB Innovations- und Gr\u00fcnderzentrum Biotechnologie.","og_description":"CatalYm combines \"good, old, effective\" antibody technology with novel biology","og_url":"https:\/\/p664637.webspaceconfig.de\/en\/izb-biotech-news\/neutralizing-gdf-15-development-of-a-new-class-of-anti-cancer-immunotherapy\/","og_site_name":"IZB Innovations- und Gr\u00fcnderzentrum Biotechnologie.","article_modified_time":"2026-07-16T14:06:27+00:00","og_image":[{"width":600,"height":383,"url":"https:\/\/p664637.webspaceconfig.de\/wp-content\/uploads\/2024\/09\/CatalYm_Video-Thumb_600x383-1.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/p664637.webspaceconfig.de\/en\/izb-biotech-news\/neutralizing-gdf-15-development-of-a-new-class-of-anti-cancer-immunotherapy\/","url":"https:\/\/p664637.webspaceconfig.de\/en\/izb-biotech-news\/neutralizing-gdf-15-development-of-a-new-class-of-anti-cancer-immunotherapy\/","name":"Neutralizing GDF-15: Development of a new class of anti-cancer immunotherapy - IZB Innovations- und Gr\u00fcnderzentrum Biotechnologie.","isPartOf":{"@id":"https:\/\/p664637.webspaceconfig.de\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/p664637.webspaceconfig.de\/en\/izb-biotech-news\/neutralizing-gdf-15-development-of-a-new-class-of-anti-cancer-immunotherapy\/#primaryimage"},"image":{"@id":"https:\/\/p664637.webspaceconfig.de\/en\/izb-biotech-news\/neutralizing-gdf-15-development-of-a-new-class-of-anti-cancer-immunotherapy\/#primaryimage"},"thumbnailUrl":"https:\/\/p664637.webspaceconfig.de\/wp-content\/uploads\/2024\/09\/CatalYm_Video-Thumb_600x383-1.jpg","datePublished":"2023-07-19T13:37:38+00:00","dateModified":"2026-07-16T14:06:27+00:00","description":"CatalYm combines \"good, old, effective\" antibody technology with novel biology","breadcrumb":{"@id":"https:\/\/p664637.webspaceconfig.de\/en\/izb-biotech-news\/neutralizing-gdf-15-development-of-a-new-class-of-anti-cancer-immunotherapy\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/p664637.webspaceconfig.de\/en\/izb-biotech-news\/neutralizing-gdf-15-development-of-a-new-class-of-anti-cancer-immunotherapy\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/p664637.webspaceconfig.de\/en\/izb-biotech-news\/neutralizing-gdf-15-development-of-a-new-class-of-anti-cancer-immunotherapy\/#primaryimage","url":"https:\/\/p664637.webspaceconfig.de\/wp-content\/uploads\/2024\/09\/CatalYm_Video-Thumb_600x383-1.jpg","contentUrl":"https:\/\/p664637.webspaceconfig.de\/wp-content\/uploads\/2024\/09\/CatalYm_Video-Thumb_600x383-1.jpg","width":600,"height":383},{"@type":"BreadcrumbList","@id":"https:\/\/p664637.webspaceconfig.de\/en\/izb-biotech-news\/neutralizing-gdf-15-development-of-a-new-class-of-anti-cancer-immunotherapy\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/p664637.webspaceconfig.de\/en\/"},{"@type":"ListItem","position":2,"name":"IZB Biotech News","item":"https:\/\/p664637.webspaceconfig.de\/izb-biotech-news\/"},{"@type":"ListItem","position":3,"name":"Neutralizing GDF-15: Development of a new class of anti-cancer immunotherapy"}]},{"@type":"WebSite","@id":"https:\/\/p664637.webspaceconfig.de\/en\/#website","url":"https:\/\/p664637.webspaceconfig.de\/en\/","name":"IZB Innovations- und Gr\u00fcnderzentrum Biotechnologie.","description":"Der Ort f\u00fcr Biotech-Start-ups in M\u00fcnchen: Labore, B\u00fcror\u00e4ume, Netzwerk!","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/p664637.webspaceconfig.de\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/p664637.webspaceconfig.de\/en\/wp-json\/wp\/v2\/izb-biotech-news\/2972","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/p664637.webspaceconfig.de\/en\/wp-json\/wp\/v2\/izb-biotech-news"}],"about":[{"href":"https:\/\/p664637.webspaceconfig.de\/en\/wp-json\/wp\/v2\/types\/izb-biotech-news"}],"version-history":[{"count":1,"href":"https:\/\/p664637.webspaceconfig.de\/en\/wp-json\/wp\/v2\/izb-biotech-news\/2972\/revisions"}],"predecessor-version":[{"id":2973,"href":"https:\/\/p664637.webspaceconfig.de\/en\/wp-json\/wp\/v2\/izb-biotech-news\/2972\/revisions\/2973"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/p664637.webspaceconfig.de\/en\/wp-json\/wp\/v2\/media\/973"}],"wp:attachment":[{"href":"https:\/\/p664637.webspaceconfig.de\/en\/wp-json\/wp\/v2\/media?parent=2972"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/p664637.webspaceconfig.de\/en\/wp-json\/wp\/v2\/categories?post=2972"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/p664637.webspaceconfig.de\/en\/wp-json\/wp\/v2\/tags?post=2972"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}